GlassScriptPhysician profile
Frank Weinberg
NPI 1952714032
$194,612.43
in general payments reported to CMS, 2019-2025
26 companies · $94K in 2025
The $94K reported for 2025 was more than what 98% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $105 · 2021: $396 · 2022: $16K · 2023: $23K · 2024: $62K · 2025: $94K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $126K · Consulting Fee: $42K · Food and Beverage: $6,845 · Travel and Lodging: $3,760 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $126,133.97 |
| Consulting Fee | $41,744.00 |
| Food and Beverage | $6,844.73 |
| Travel and Lodging | $3,759.61 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $87,588.76 | 2022-2025 | Zepzelca |
| Amgen INC. | $36,361.30 | 2022-2025 | Imdelltra (Amg757), Lumakras |
| Regeneron Healthcare Solutions, INC. | $36,308.02 | 2022-2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $8,764.92 | 2023-2025 | Imfinzi, Tagrisso |
| Janssen Biotech, INC. | $6,800.97 | 2025 | Rybrevant, Carvykti |
| Eli Lilly and Company | $6,101.00 | 2025 | |
| Pharmacosmos Therapeutics INC. | $4,297.27 | 2024-2025 | Cosela |
| Abbvie INC. | $2,946.46 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $2,177.27 | 2022-2024 | Libtayo |
| Genzyme Corporation | $1,140.00 | 2022 | |
| Lilly USA, LLC | $357.14 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.55 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $258.11 | 2021-2025 | Keytruda, Welireg, Lynparza |
| G1 Therapeutics, INC. | $253.02 | 2022-2023 | Cosela |
| Aveo Pharmaceuticals, INC. | $238.18 | 2023 | Fotivda |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $135.71 | 2020-2022 | |
| Pfizer INC. | $135.00 | 2024 | |
| Tempus Ai, INC | $133.65 | 2024-2025 | Xt Cdx |
| Daiichi Sankyo INC. | $79.00 | 2024 | Enhertu |
| Genentech USA, INC. | $68.00 | 2025 | |
| Bard Peripheral Vascular, INC. | $58.16 | 2025 | Pleurx |
| Emd Serono, INC. | $43.52 | 2023 | Bavencio, Tepmetko |
| Immunocore Limited | $30.46 | 2024 | |
| Novartis Pharmaceuticals Corporation | $24.86 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.10 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Weinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.